

## What were the top 20 global M&A transactions of 2012?

12 June 2013 | Analysis | By BioSpectrum Bureau



A majority of life science firms are standing on the edge of the patent cliff and their drug pipelines are experiencing acute scarcity. This is making them seek out partners for mergers & acquisitions (M&A).

**Also read:**

â€¢ [Why did mergers & acquisitions plunge in APAC?](#)

â€¢ [What are the key mergers & acquisitions of Q1 2013?](#)

Furthermore, the urge to strengthen their existing product portfolios and enter into new markets has fuelled what can be called the mergers & acquisitions (M&A) galore during the first quarter of 2013. The following have been the 'Top 20 Global M&A Transactions in 2012'.

## Top 20 Global Transactions in 2012

S.No	Acquirer	Target	Deal Value (in \$ bn)
1	BMS	Amylin	7.00
2	Watson	Actavis	5.50
3	Hologic	Gen-Probe	3.80
4	GSK	Human Genome Sciences	3.60
5	Dainippon	Boston Biomedical	0.20 (milestone payments upto 0.54)
6	Valeant	Medicis	2.60
7	Bristol-Myers Squibb	Inhibitex	2.50
8	Agilent	Dako	2.20
9	TPG	Par Pharmaceuticals	1.80
10	Amgen	Micromet	1.60
11	Sandoz	Fougera	1.50
12	Astrazene	Ardea	1.30
13	CSPC Pharmaceutical Group	CSPC NBP Pharmaceutical	1.18
14	China Pharmaceutical Group	Robust Sun	1.15
15	Alexion	Enobia	1.08
16	Thermo Fisher	One Lambda	0.92
17	Celgene	Avila	0.35 (milestone payment upto 0.57)
18	Takeda	URL Pharma	0.80
19	Smith & Nephew	Healthpoint	0.78
20	Corning	Becton Dickinson	0.72
Source: IMAF, Global Pharma & Biotech M&A Report, 2013			